239 related articles for article (PubMed ID: 16292117)
1. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
[TBL] [Abstract][Full Text] [Related]
2. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
N Engl J Med; 2001 Apr; 344(17):1279-85. PubMed ID: 11323729
[TBL] [Abstract][Full Text] [Related]
3. Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Jaffe RJ; Juneja NS; Juneja NS; Jaffe RJ; Coffey BJ
J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):488-490. PubMed ID: 30226805
[No Abstract] [Full Text] [Related]
4. Fluvoxamine for the treatment of anxiety disorders in children and adolescents.
Isaacs E
N Engl J Med; 2001 Aug; 345(6):466-7. PubMed ID: 11496864
[No Abstract] [Full Text] [Related]
5. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
6. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
8. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
Houck C
Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
Cheer SM; Figgitt DP
CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
[TBL] [Abstract][Full Text] [Related]
10. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
Reinblatt SP; DosReis S; Walkup JT; Riddle MA
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
[TBL] [Abstract][Full Text] [Related]
11. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.
Abikoff H; McGough J; Vitiello B; McCracken J; Davies M; Walkup J; Riddle M; Oatis M; Greenhill L; Skrobala A; March J; Gammon P; Robinson J; Lazell R; McMahon DJ; Ritz L;
J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):418-27. PubMed ID: 15843763
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
13. The luvox debate.
Dickinson A
Time; 2001 May; 157(18):76. PubMed ID: 11373801
[No Abstract] [Full Text] [Related]
14. Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study.
Schirman S; Kronenberg S; Apter A; Brent D; Melhem N; Pick N; Carmel M; Frisch A; Weizman A; Gothelf D
J Neural Transm (Vienna); 2010 Jan; 117(1):139-45. PubMed ID: 19851705
[TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and safety of fluvoxamine and other antidepressants.
Westenberg HG; Sandner C
Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
[TBL] [Abstract][Full Text] [Related]
17. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.
Asakura S; Tajima O; Koyama T
Int J Neuropsychopharmacol; 2007 Apr; 10(2):263-74. PubMed ID: 16573847
[TBL] [Abstract][Full Text] [Related]
18. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis.
Rausch JL; Hobby HM; Shendarkar N; Johnson ME; Li J
J Clin Psychopharmacol; 2001 Apr; 21(2):139-42. PubMed ID: 11270909
[TBL] [Abstract][Full Text] [Related]
19. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
Dalery J; Honig A
Hum Psychopharmacol; 2003 Jul; 18(5):379-84. PubMed ID: 12858325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
